Dominik Dornbierer
Clinical Pharmacologist
Papers
Trials
Key Impact
Notable for leading translational clinical research on co‑administered N,N‑dimethyltryptamine and harmine, integrating pharmacokinetics, pharmacodynamics, neuroimaging and behavioural outcomes.
Background & Research
Dominik A. Dornbierer is a clinical pharmacologist and researcher focused on the acute human pharmacology of psychedelic tryptamines and beta‑carbolines. His recent work centres on ayahuasca‑inspired formulations combining N,N‑dimethyltryptamine (DMT) with harmine, investigating dose–response relationships, pharmacokinetic–pharmacodynamic interactions and population PK‑PD modelling in healthy volunteer cohorts. Dornbierer has been involved in randomised controlled studies examining psychological outcomes such as mindfulness and compassion, experimental paradigms probing creativity during artistic creation, and neuroimaging work exploring self–other face differentiation under DMT/harmine influence.
He brings methodological expertise in factorial dose‑escalation designs, population pharmacokinetic and pharmacodynamic modelling, and multimodal outcome assessment (behavioural, psychometric and neuroimaging). Dornbierer’s contributions aim to characterise safety, acute subjective effects and mechanistic markers that can inform dose selection and translational development of serotoninergic psychedelic compounds for psychiatric research.